Background: The introduction of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus-1 (HIV-1) prevention in Africa presents new challenges for health systems that are already overburdened because PrEP delivery requires frequent clinic visits (generally every 3 months) for HIV-1 testing and PrEP refills. HIV-1 self-testing (HIVST) has the potential to improve the efficiency of PrEP delivery by decreasing the number of clinic visits. Here, we describe the rationale and design of a randomized, noninferiority trial designed to test the effectiveness and safety of using HIVST to support PrEP delivery in Kenya.
Methods: The JiPime-JiPrEP (Kiswahili for 'Test Yourself, PrEP Yourself') study is a three-arm randomized trial taking place in Thika, Kenya. Participants (n = 495) are eligible for enrollment if they are at least 18 years old, HIV-1 seronegative, and have been taking PrEP for 1 month. Three distinct participant types will be enrolled: men (n = 165) and women (n = 165) who are in mutually disclosed HIV-1 serodiscordant relationships, and women (n = 165) who are at HIV-1 risk and not in a known serodiscordant relationship. Participants in each of these subpopulations will be 1:1:1 randomized to: 1) the standard of care, with quarterly clinic visits; 2) oral HIVST, with biannual clinic visits plus oral HIVSTs to use at the quarters between those visits; or 3) blood-based HIVST, with biannual clinic visits plus blood-based HIVSTs. All participants will complete quantitative surveys and provide blood samples for the objective measurement of PrEP adherence at baseline, 6 months, and 12 months. The primary outcomes are PrEP adherence, PrEP continuation, and HIV-1 testing, measured at 6 months and secondarily at 12 months.
Discussion: The findings from this trial can help to understand how HIVST-a new HIV-1 testing technology-can support health systems in sub-Saharan Africa. Additionally, the findings can inform policy aimed at improving the efficiency of PrEP implementation and scale-up in Kenya.
Trial Registration: ClinicalTrials.gov, NCT03593629 . Retrospectively registered on 20 July 2018.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610957 | PMC |
| http://dx.doi.org/10.1186/s13063-019-3521-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Barriers to Interconception Care Delivery in Primary Care: Clinician, Staff, and Patient Perspectives.
Womens Health Rep (New Rochelle)
December 2024
Department of Family Medicine, University of Chicago, Chicago, Illinois, USA.
Purpose: Many reproductive age women, cared for routinely by primary care providers (PCPs), would benefit from interconception care, yet a minority of primary care visits include interconception care. This study assessed barriers to providing interconception care from the perspective of primary care clinicians, staff, and patients.
Materials And Methods: Clinicians ( = 11), staff ( = 14), and patients eligible for interconception care ( = 6) from three primary care clinics in Chicago, Illinois participated in focus groups or interviews.
Case Series of Vaccine Hesitancy Encountered at the Pediatric Emergency Department.
Cureus
November 2024
Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu-shi, JPN.
Vaccine hesitancy (VH) is a significant concern, although its specific characteristics remain unclear. Moreover, strategies to shift vaccine-hesitant parents' attitudes toward immunization are not yet well-defined. Pediatric emergency department (ED) physicians frequently encounter patients who are inadequately vaccinated due to parental VH; however, it is challenging to allocate sufficient time during ED visits to provide comprehensive vaccination education.
View Article and Find Full Text PDFImproved Adherence to Lipid Screening in the Pediatric Cardiology Clinic: A Quality Improvement Project.
Pediatr Qual Saf
December 2024
From the Division of Pediatric Cardiology, Morristown Medical Center, Atlantic Health System, Morristown, N.J.
Introduction: Lipid screening identifies at-risk patients to facilitate cardiovascular risk reduction. National pediatric guidelines recommend universal lipid screening between 9-11 and 17-21 years of age. We aimed to improve adherence to lipid screening for all age-appropriate outpatient pediatric cardiology visits from a baseline of 35% to 90% between November 2021 and July 2023.
View Article and Find Full Text PDFSurvival after aluminum phosphide poisoning with cardiotoxicity: a case report.
J Med Case Rep
December 2024
Department of Internal Medicine, Woldia Comprehensive Specialized Hospital, Woldia, Ethiopia.
Introduction: Aluminum phosphide is a cheap and commonly used rodenticide that is also an effective solid fumigant and frequently used for grain preservation. The pill contains around 44% inert elements (ammonium carbonate) to avoid disintegration of the tablet, while the rest (about 56%) is aluminum phosphide. Because it is freely available on the market, it is one of the commonly used agents for self-poisoning in different parts of the developing world.
View Article and Find Full Text PDFAccelerometer-based sedentary time and physical activity with incident and progressive tobacco smoking in 2503 children: A 13-year mediation and temporal longitudinal study.
Behav Res Ther
December 2024
Institute of Public Health and Clinical Nutrition, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland; Children's Health and Exercise Research Centre, Department of Public Health and Sports Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, UK. Electronic address:
Background: Long-term accelerometer-based studies examining whether engaging in physical activity (PA) reduces the risk of smoking in children are lacking, and whether directly measured adiposity increases smoking risk is uncertain.
Methods: From the Avon Longitudinal Study of Parents and Children (ALSPAC), UK birth cohort, 2503 children aged 11 years with complete smoking and at least one valid time-point movement behaviour data were followed up until age 24 years. ActiGraph assessed sedentary time (ST), light PA (LPA), and moderate-to-vigorous PA (MVPA) at ages 11, 15, and 24-year clinic visits and smoking-based questionnaires were administered, whilst fat mass was measured with dual-energy x-ray absorptiometry scanner.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!